Scientists for the first time have used CRISPR gene editing to halt the progression of Duchenne muscular dystrophy (DMD) in a large mammal, according to a study by UT Southwestern that provides a strong indication that a lifesaving treatment may be in the pipeline.
The research published in Science documents unprecedented improvement in the muscle fibers of dogs with DMD – the most common fatal genetic disease in children, caused by a mutation that inhibits the production of dystrophin, a protein critical for muscle function.
Researchers used a single-cut gene-editing technique to restore dystrophin in muscle and heart tissue by up to 92 percent of normal levels. Scientists have estimated a 15 percent threshold is needed to significantly help patients.
“Children with DMD often die either because their heart loses the strength to pump, or their diaphragm becomes too weak to breathe,” said Dr. Eric Olson, Director of UT Southwestern’s Hamon Center for Regenerative Science and Medicine. “This encouraging level of dystrophin expression would hopefully prevent that from happening.”
DMD, which affects one in 5,000 boys, leads to muscle and heart failure, and premature death by the early 30s. Patients are forced into wheelchairs as their muscles degenerate and eventually onto respirators as their diaphragms weaken. No effective treatment exists, though scientists have known for decades that a defect in the dystrophingene causes the condition.
The Science study establishes the proof-of-concept for single-cut gene editing in dystrophic muscle and represents a major step toward a clinical trial. Already Dr. Olson’s team has corrected DMD mutations in mice and human cells by making single cuts at strategic points of the mutated DNA.
The latest research applied the same technique in four dogs that shared the type of mutation most commonly seen in DMD patients. Scientists used a harmless virus called adeno-associated virus (AAV) to deliver CRISPR gene-editing components to exon 51, one of the 79 exons that comprise the dystrophin gene.
CRISPR edited the exon, and within several weeks the missing protein was restored in muscle tissue throughout the body, including 92 percent correction in the heart and 58 percent in the diaphragm, the main muscle needed for breathing.
“Our strategy is different from other therapeutic approaches for DMD because it edits the mutation that causes the disease and restores normal expression of the repaired dystrophin,” said Dr. Leonela Amoasii, lead author of the study and Assistant Instructor of Molecular Biology in Dr. Olson’s lab. “But we have more to do before we can use this clinically.”
The lab will next conduct longer-term studies to measure whether the dystrophin levels remain stable and to ensure the gene edits do not have adverse side effects.
Dr. Olson hopes the next step beyond dogs is a clinical trial, which would be among several that UT Southwestern’s gene therapy center aims to launch in the coming years to address numerous deadly childhood diseases.
In the meantime, Dr. Olson’s recent work has spawned a biotechnology company, Exonics Therapeutics Inc., which is working to further optimize and bring this technology to the clinic. Exonics intends to extend the approach to additional DMD mutations, as well as other neuromuscular diseases. Exonics has licensed the technology from UT Southwestern.
The Latest on: Duchenne muscular dystrophy
via Google News
The Latest on: Duchenne muscular dystrophy
- Binghamton University to use $329K grant for research on Duchenne muscular dystrophy on December 26, 2018 at 11:54 am
VESTAL, N.Y. — A Binghamton University professor will use grant funding of $329,000 for research focused on Duchenne muscular dystrophy (DMD). Kanneboyina Nagaraju, professor and chair of the departme... […]
- U.S. drug developer Capricor places Duchenne drug trial on hold on December 26, 2018 at 6:29 am
(Reuters) - Capricor Therapeutics Inc said on Wednesday it had put on hold a clinical trial of its drug to treat Duchenne muscular dystrophy (DMD), a muscle-wasting disorder, citing a safety review. […]
- Little Capricor hits the brakes on a stem cell trial for Duchenne MD following an allergic reaction on December 26, 2018 at 3:52 am
The biotech noted that it has voluntarily halted a clinical trial of a stem cell therapy they had hoped would tamp down on the damaging inflammation associated with Duchenne muscular dystrophy. […]
- Capricor places Duchenne drug trial on hold on December 26, 2018 at 3:49 am
(Reuters) - Capricor Therapeutics Inc said on Wednesday it had put on hold a clinical trial of its drug to treat Duchenne muscular dystrophy, a muscle-wasting disorder. The hold was due to an ongoing ... […]
- Honey family in American Fork gifted new yellow van for Christmas on December 24, 2018 at 2:02 pm
Three of Mark and Sharon Honey’s boys all have Duchenne muscular dystrophy. Josh, 15, Andrew, 14, and Anthony, 12, must use motorized wheelchairs to get around. Prior to this gift, if the Honey family ... […]
- Aw! 6-year-old with muscular dystrophy proposes to art teacher at Duke Children's on December 21, 2018 at 1:47 pm
Durham, N.C. — Aw! A 6-year-old boy with Duchenne muscular dystrophy recently popped the question to his art teacher at Duke Children's Hospital. Creed, who is from the Fayetteville area, has been tre... […]
- SUMMIT THERAPEU/S (SMMT) Lowered to Strong Sell at Zacks Investment Research on December 21, 2018 at 9:15 am
According to Zacks, “Summit Therapeutics PLC is engaged in the discovery and development of drug to treat the fatal muscle wasting disease Duchenne Muscular Dystrophy and infections caused by the bact... […]
- Parent Project Muscular Dystrophy Awards $329,000 Grant to Binghamton University to Examine the Role of the Immune System on Dystrophin Restoration on December 19, 2018 at 7:18 am
HACKENSACK, N.J., Dec. 19, 2018 /PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), announced plans to a... […]
- Monitoring Lung Function at Home In Teens With Duchenne Muscular Dystrophy on December 18, 2018 at 6:19 pm
Heart and lung complications are responsible for much of the morbidity and mortality associated with Duchenne muscular dystrophy (DMD). Although regular monitoring of pulmonary function is recommended ... […]
- Home-Based Monitoring of Lung Function More Effective for Teens with Duchenne Muscular Dystrophy on December 18, 2018 at 1:56 am
Regular monitoring of lung function at home can be more convenient and effective for teens with Duchenne muscular dystrophy (DMD), reports a new study. The findings of the study are published in the J... […]
via Bing News